Copy Link Print Information

Durvalumab (anti-PD-L1)

(Synonyms: MEDI 4736 (anti-PD-L1))
6 Cited Publications
Customer Review

Based on 6 publication(s) in Google Scholar

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity.

For research use only. We do not sell to patients.

  • Purity: 99.0%
  • CAS No.: 1428935-60-7
  • Molecular Weight:146.32 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Durvalumab (anti-PD-L1)
  • Experimental Validation Results for Durvalumab (anti-PD-L1)
  • Experimental Validation Results for Durvalumab (anti-PD-L1)
  • Experimental Validation Results for Durvalumab (anti-PD-L1)
  • Experimental Validation Results for Durvalumab (anti-PD-L1)
  • Experimental Validation Results for Durvalumab (anti-PD-L1)
  • Experimental Validation Results for Durvalumab (anti-PD-L1)
  • Durvalumab (anti-PD-L1) Chemical Structure
    Durvalumab (anti-PD-L1) Chemical Structure
CAS No.: 1428935-60-7
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Durvalumab (anti-PD-L1):

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Durvalumab (anti-PD-L1)

More
Customer Validation & Images
Bio/Physico-chemical AssayIn Vivo Efficacy StudyHistological Imaging/Staining
  • Bio/Physico-chemical Assay
  • Bio/Physico-chemical Assay
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • Histological Imaging/Staining
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometry analysis of PD-L1 overexpression CHO cells labelling PD-L1 with Durvalumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

  • 1/16

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

    Customer Validation
     Migration-focused results of ECIS tests on T98G and U87 glioblastoma cells treated with Radiation and Durvalumab. Representative plot of normalized resistance in the first 40 hours posttreatment for T98G.

  • 1/16

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

    Customer Validation
     Barrier function-focused results of ECIS tests on T98G glioblastoma cells treated with radiation and durvalumab. Representative plot of the barrier function Rb posttreatment for T98G shown.

  • 1/16

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]

    Customer Validation
     4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. The tumor growth was monitored twice per week. n=8 mice per group.

  • 1/16

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]

    Customer Validation
     Survival curve of the mice of the combination of Cam, NGI-1 nanoparticle and Durvalumab (5 mg/kg, i.p., 3 times). n=8 mice per group.

  • 1/16

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]

    Customer Validation
     4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. Tumor tissues were subjected to the immunohistochemically staining with anti-CD8 antibody.

  • Durvalumab (anti-PD-L1) Chemical Structure
    1/16
  • Durvalumab (anti-PD-L1)
  • Flow cytometry analysis of PD-L1 overexpression CHO cells labelling PD-L1 with Durvalumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).